GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » EV-to-Revenue

Relief Therapeutics Holding (XSWX:RLF) EV-to-Revenue : 0.74 (As of May. 16, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Relief Therapeutics Holding's enterprise value is CHF4.45 Mil. Relief Therapeutics Holding's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF6.03 Mil. Therefore, Relief Therapeutics Holding's EV-to-Revenue for today is 0.74.

The historical rank and industry rank for Relief Therapeutics Holding's EV-to-Revenue or its related term are showing as below:

XSWX:RLF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.12   Med: 14.5   Max: 2112.17
Current: 0.74

During the past 13 years, the highest EV-to-Revenue of Relief Therapeutics Holding was 2112.17. The lowest was 0.12. And the median was 14.50.

XSWX:RLF's EV-to-Revenue is ranked better than
89.72% of 1041 companies
in the Biotechnology industry
Industry Median: 8.07 vs XSWX:RLF: 0.74

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-16), Relief Therapeutics Holding's stock price is CHF1.28. Relief Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.52. Therefore, Relief Therapeutics Holding's PS Ratio for today is 2.49.


Relief Therapeutics Holding EV-to-Revenue Historical Data

The historical data trend for Relief Therapeutics Holding's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding EV-to-Revenue Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 64.47 19.07 2.21

Relief Therapeutics Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.47 - 19.07 - 2.21

Competitive Comparison of Relief Therapeutics Holding's EV-to-Revenue

For the Biotechnology subindustry, Relief Therapeutics Holding's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's EV-to-Revenue falls into.



Relief Therapeutics Holding EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Relief Therapeutics Holding's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4.452/6.033
=0.74

Relief Therapeutics Holding's current Enterprise Value is CHF4.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF6.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding  (XSWX:RLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Relief Therapeutics Holding's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.28/0.515
=2.49

Relief Therapeutics Holding's share price for today is CHF1.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (XSWX:RLF) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (XSWX:RLF) Headlines

No Headlines